Iterum Therapeutics PLC

ITRMF Healthcare Biotechnology

In the quarter to September 2025, revenue grew 110.8%, EPS grew 33.3% and free cash flow fell 179.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.00 0.00 NaN
Market cap
$1.6M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
2/9
Altman Z
−26.27
Beneish M
22.81
Dividend safety
n/a
Older periods Dec '24 Mar '25 Jun '25 Sep '25
ROE

+8 more TTM periods

472.61% 518.47% 325.35% 285.48%
ROA
(69.93%) (85.79%) (99.93%) (111.35%)
ROIC
0.00% (184.61%) (297.39%) (455.51%)
Return on Tangible Assets
(343.84%) (227.85%) (256.98%) (368.57%)
Average Days of Receivables
0.00 — — 177.74
Free Cash Flow per Share
(1.36) (0.49) (0.37) (0.43)
Free Cash Flow
(26.77) (16.75) (14.74) (19.53)
Other line items

Show all line items

Columns are period end dates